Anti-Mouse MHC Class I (H-2Db) Monoclonal Antibodies

PA007591.m2a: In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Db) Monoclonal Antibody (Clone: 28-14-8S), Mouse IgG2a Kappa

Recombinant Mouse IgG2a Monoclonal Antibody.
Clone: 28-14-8S.
Isotype: Mouse IgG2a Kappa.
Source: The anti-mouse MHC Class I (H-2Db) monoclonal antibody (clone: 28-14-8S) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 28-14-8S) specifically binds to mouse MHC Class I (H-2Db).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse MHC Class I (H-2Db) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse MHC Class I (H-2Db) monoclonal antibody of clone 28-14-8S is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-mouse MHC Class I (H-2Db) Monoclonal Antibody:

Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
Tokita, S., et al. Sci Adv. 2024 Sep 20;10(38):eado6491. doi: 10.1126/sciadv.ado6491. PMID: 39292790
The peptides bound to MHC-I or MHC-II were captured as peptide-MHC complexes using affinity chromatography of W6/32 monoclonal antibody (mAb) for pan HLA-I (HB-95, ATCC), IVA12 mAb for pan HLA-II (HB-145, ATCC), BB7.2 mAb for HLA-A2 (HB-82, ATCC), SF1-1.1.10 mAb for H-2Kd (HB-159, ATCC), 34-5-8S mAb for H-2Dd (HB-102, ATCC), or 28-14-8S mAb for H-2Ld (HB-27, ATCC) coupled to CNBr-activated Sepharose 4B (GE Healthcare) overnight. ...In contrast, an in silico prediction algorithm (NetMHCpan4.1) combined with RNA sequencing (RNA-seq) gene expression data predicted 326 candidate neoantigens potentially presented by HLA-A*02:01 from the same mutation data (see Materials and Methods for details). ...The in silico–predicted neoantigens consisted of 126 strong binders (%rank NetMHC scores below 0.5) and 200 weak binders (%rank NetMHC scores below 2.0), and we evaluated all 126 strong binders using the tandem IVTT method. ...Meanwhile, in silico prediction using NetMHCpan and RNA-seq data predicted 326 HLA-A*02:01 and 312 HLA-I candidate neoantigens (%rank NetMHC scores below 2.0) in CRC135 and UTE003, respectively (Figs. 2A and 3A). ...Potential de novo neoantigens were defined as those with wild-type and neoantigen NetMHCpan4.1 scores greater than and less than 2.0, respectively.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S; anti-mouse MHC Class I (H-2Db) 28-14-8S mAb

Transposable elements regulate thymus development and function.
Larouche, J.-D., et al. Elife. 2024 Apr 18:12:RP91037. doi: 10.7554/eLife.91037. PMID: 38635416
Intrathymic generation of a functional T-cell repertoire depends on choreographed interactions between the TCRs of thymocytes and peptides presented by major histocompatibility complex (MHC) molecules on various antigen-presenting cells (APCs) (Zuñiga-Pflucker et al., 1989). ...Since some TEs are translated and generate MHC I-associated peptides (MAP) (Larouche et al., 2020), they might induce TE-specific central tolerance (Kassiotis, 2023). ...Following cell lysis and MHC I immunoprecipitation, MAPs were analyzed by liquid chromatography MS/MS (Figure 6a). ...MHC I complexes were eluted from the beads by acidic treatment using 1% trifluoroacetic acid (TFA). ...Acidic filtrates containing peptides were separated from MHC I subunits (HLA molecules and β–2 microglobulin) using home-made stage tips packed with two 1 mm diameter octadecyl (C-18) solid phase extraction disks (EMPORE).
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S in vivo; anti-mouse MHC Class I (H-2Db) 28-14-8S in animal model

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
Iorgulescu, J. B., et al. Front Immunol. 2023 Dec 28:14:1297932. doi: 10.3389/fimmu.2023.1297932. PMID: 38213329
The availability of high-quality MHC class I neoantigen candidates did not appear to differ between the two lines, as they both demonstrated similar proportions of highly-expressed strong predicted HLA class I binders. ...MHC class I binding strength was categorized as strong (percentile rank < 0.5), weak (0.5 ≤ percentile rank < 2.0), or none (percentile rank ≥ 2.0). ...Deficiency in the peptide loading complex may limit the peptides available for binding to MHC class I, and accordingly, the successful assembly of MHC class I molecules for surface expression. ...However, MHC class I surface expression was strongly upregulated by IFN-γ treatment in both lines (all padjusted ≤ 0.001; Figure 3F; Supplementary Figure 4D), potentially suggesting that the Tap1 mutational defect and impaired antigen presentation machinery in CT2A could be – at least partially – overcome by exposure to exogenous IFN-γ. ...We found that CT2A-luc intrinsically shared these mechanisms, but we also observed that exogenous IFN-γ treatment could at least partially restore MHC class I expression in CT2A-luc – suggesting that select multi-pronged immunotherapeutic strategies may overcome CT2A’s inherent resistance to immunotherapy.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in cancer research; anti-mouse MHC Class I (H-2Db) 28-14-8S in mouse tumor model

Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors.
Hoover, A. R., et al. Journal for ImmunoTherapy of Cancer. 2022 Oct;10(10):e004973. doi: 10.1136/jitc-2022-004973. PMID: 36253002
The monoclonal antibodies (clones 28-14-8 (anti-Db) and AF6-88.5.5.3 (anti-Kb)) were used to isolate the MHC class I alleles (Db and Kb) and purify the Db-associated and Kb-associated peptides from the tumors as well as staining of the B16-F10 cells to determine cell surface expression of Db and Kb using flow cytometry. ...To determine the expression of the MHC class I molecules (Db and Kb) on the surface of B16-F10 cells, they were seeded at 5×105 cells/well in 6-well plates in complete growth medium. ...In contrast to B16-F10 tumor cells cultured in vitro which express little-to-no H2-Db or H2-Kb molecules unless treated with IFN-γ (online supplemental figure 2A,B), implanted tumor cells yielded high quantities of MHC class I molecules in vivo. This high expression resulted in the identification of hundreds of H2-Db and H2-Kb tumor-associated peptides. ...To identify the TSAs that were exclusively presented by B16-F10 tumor cells and were absent from healthy tissues, the tumor peptidome was searched against a map of murine MHC class I immunopeptidome generated from different tissues of healthy C57BL/6 mice18 and the peptides expressed on healthy tissues were eliminated. ...The anti-Kb monoclonal antibody (clone AF6-88.5.5.3) was purchased from BioXcell. Anti-Db (28-14-8S, ATCC) hybridoma was grown in serum-free media and purified in-house using Protein G Sepharose column (GE Healthcare, Sweden).
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S antibody of low endotoxin; anti-mouse MHC Class I (H-2Db) (28-14-8S) in vivo antibody

Direct Priming of CD8+ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation.
Lin, L. C. W., et al. J Virol. 2021 Apr 26;95(10):e00186-21. doi: 10.1128/JVI.00186-21. PMID: 33692206
First, degradation of different MHC-I alleles is not the same for US2 and US11; second, US2 can also degrade MHC class II; third, the downregulation of de novo viral antigen presentation on infected cells was not especially strong in these studies. ...After clearing the lysate by centrifugation, the peptide-MHC within the supernatant was isolated via immunoaffinity purification using sequential anti-Kb (clone Y-3) and anti-Db (clone 28-14-8S) antibodies cross-linked to protein A Sepharose. ...For peptide detection and quantitation, LC-MRM was employed for a panel of known VACV epitopes whose MRM transition parameters have previously been optimized. ...Statistical analysis was conducted with GraphPad Prism software or with R. ...All cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and l-glutamine.
Tags: anti-MHC Class I (H-2Db) clone 28-14-8S; clone 28-14-8S of mouse MHC Class I (H-2Db) antibody

Identification and Characterization of Rift Valley Fever Virus-Specific T Cells Reveals a Dependence on CD40/CD40L Interactions for Prevention of Encephalitis.
Barbeau, D. J., et al. J Virol. 2021 Nov 9;95(23):e0150621. doi: 10.1128/JVI.01506-21. PMID: 34495703
Following a 2-day incubation, MHC-bound radioactivity was determined by capturing MHC/peptide complexes on Lumitrac 600 plates (Greiner Bio-One, Frickenhausen, Germany) coated with either Y3 (anti-H-2-Kb), 28-14-8s (anti-H-2-Db, Ld, and Dq), or Y3JP (anti-H-2-IAb,s,u) monoclonal antibodies; bound counts per minute were measured using the TopCount (Packard Instrument Co., Meriden, CT) microscintillation counter. ...Research with live virus was conducted at the Center for Vaccine Research’s Regional Biocontainment Laboratory or at the Centers for Disease Control and Prevention (CDC) under biosafety level 3 (BSL3) conditions. ...Institutional Animal Care and Use Committee approval was provided by the University of Pittsburgh (protocol no. 17080998 and 19044158) or CDC (protocol no. 2577MCEMOUC or 2629MCEMOUC). ...All recombinant virus work was approved by the respective institutional biosafety committees. ...Previously, CD4 T cells were identified as a critical component of adaptive immunity that prevented RVFV-mediated encephalitis.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S; anti-mouse MHC Class I (H-2Db) 28-14-8S antibody

Palladium-Induced Temporal Internalization of MHC Class I Contributes to T Cell-Mediated Antigenicity.
Ito, K., et al. Front Immunol. 2021 Dec 23:12:736936. doi: 10.3389/fimmu.2021.736936. PMID: 35003059
In this concept, haptenated antigens phagocytosed by APCs are cross-presented by MHC class I after undergoing processing (12). ...In other words, the peptide loading onto the MHC class I is derived from haptenated antigens. ...In some experiments, prior to co-culture with TG40 cells, peptides on MHC class I were stripped as described previously. ...Surface MHC class I expression after PdCl2 treatment. ...First, we asked whether Pd-treatment affects MHC class I/peptide complexes. To examine this, mice were injected with ovalbumin (OVA) protein and 12 hours after injection, PdCl2 was injected intraperitoneally.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S in vivo; anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in vivo

Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.
Nagaoka, K., et al. Cancers (Basel). 2021 Dec 27;14(1):106. doi: 10.3390/cancers14010106. PMID: 35008270
The peptide-MHC class I complexes were captured by affinity chromatography using purified monoclonal antibodies (clone Y-3 for Kb and 28-14-8S for Db) coupled to CNBr-activated Sepharose 4B (GE Healthcare, Chicago, IL, USA). ...Peptides bound to MHC class I were eluted with a mild acid (0.2% TFA) and desalted using a Sep-Pak C18 cartridge (Waters Corporation, Milford, MA, USA) with 28% ACN in 0.1% TFA and ZipTip U-C18 (Merck Millipore, Burlington, MA, USA) with 50% ACN in 1% FA. ...MHC class I binding peptides were eluted from viable YTN16 cells as described previously. ...Neoepitopes derived from the products of these mutated genes were predicted by their estimated binding capacity to MHC class I molecules; 8-, 9-, and 10-mer peptides containing the mutated amino acid were assessed by NetMHCpan and MHCflurry algorithms to predict their binding to and presentation on H-2Db and H-2Kb molecules. ...In silico-predicted peptides indeed stabilized MHC class I expression on RMAS cells.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S in animal model; anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in animal model

Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses.
Wu, T., et al. Nat Commun. 2019 Jun 28;10(1):2846. doi: 10.1038/s41467-019-10661-8. PMID: 31253788
The above data represent the first in-depth analysis of the differential abundance of virus peptides presented by MHC class I complexes via the routes of direct versus cross-presentation. ...After centrifugation, the MHC/peptide in the supernatant were captured sequentially by immunoaffinity purification using columns containing protein A sepharose (GE Healthcare) conjugated to firstly Y-3 (anti-H-2Kb) and then 28-14-8s (anti-H-2Db) monoclonal antibody. ...Following a 2-day incubation, MHC-bound radioactivity was determined by capturing pMHCI complexes on Lumitrac 600 plates (Greiner Bio-one, Frickenhausen, Germany) coated with either the Y3 (anti-H-2 Kb) or 28-14-8s (anti-H-2Db, Ld and Dq) monoclonal antibodies, and bound cpm measured using the TopCount (Packard Instrument Co., Meriden, CT) microscintillation counter. ...The concentration of peptide yielding 50% inhibition of binding of the radiolabeled peptide was calculated and, under the conditions utilized, where [label] < [MHC] and IC50 ≥ [MHC], measured IC50 values are reasonable approximations of true Kd. ...Acquired spectra were searched against the combined IAV and mouse proteome database (Uniprot; March 2015) using ProteinPilot™ (SCIEX) and the resulting combined search file used for spectral library generation in Skyline. For SWATH-MS acquisition, the following acquisition scheme was used: 250 ms MS1 scan across 300–1800 m/z, followed by 28 sequential SWATH windows of 25 Da each (1 Da overlap) from 300 to 1000 m/z. For each window, MS2 spectra were acquired for 100 ms across a scan range of 100–1800 m/z.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in cancer research; anti-mouse MHC Class I (H-2Db) 28-14-8S in mouse tumor model

A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer.
DeVette, C. I., et al. Oncoimmunology. 2019 Nov 29;9(1):1685300. doi: 10.1080/2162402X.2019.1685300. PMID: 32002300
Unfortunately, studying tumor immunology in FVB mice is difficult due to lack of characterization of the MHC class I alleles in this H-2q haplotype strain. ...In order to enable the study of tumor immunity in this mouse model, we recently defined the MHC class I alleles of the FVB/NJ strain, characterized their peptide binding properties, and developed the NetH2pan prediction tool.Citation1. ...Importantly, the strongest predicted binder was not always presented by a cell since MHC class I peptide presentation is the culmination of proteosomal cleavage, peptide trimming, and trafficking to the cell surface. ...Pooled spontaneous MMTV-PyMT tumors provided sufficient tissue for class I MHC pull-down followed by peptide extraction and proteomic identification. ...The application of SWATH proteomic data acquisition identified an additional PyMT peptide (MT241-250), along with MT288-296 and MT326-335, both of which had initially been identified using sMHC and tumor-eluted DDA data.
Tags: anti-mouse MHC Class I (H-2Db) antibody 28-14-8S; clone 28-14-8S of anti-mouse MHC Class I (H-2Db) antibody

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.
Covre, A., et al. Oncoimmunology. 2015 Apr 2;4(8):e1019978. doi: 10.1080/2162402X.2015.1019978. PMID: 26405573
The immunomodulatory activity of 5-AZA-CdR combined with mAb 9H10 was investigated in TS/A tumors excised one week after the end of treatment from three randomly selected treated and control mice; changes in the expression of different murine Cancer Testis Antigen (i.e., tumor rejection antigen P1A (P1A) and Melanoma Antigen A (Mage-a) family members) and of MHC class I antigens were utilized as readouts. ...Representative results of the immunohistochemical analysis for the expression of MHC class I antigens reported in Fig. ...The extensive necrosis of tumors from mice treated with 5-AZA-CdR combined with mAb 9H10 allowed a conclusive interpretation on the changes of MHC class I antigens expression only in two animals (data not shown). ...Modulation of MHC class I antigen expression and T cell infiltration by 5-AZA-CdR combined with mAb 9H10 in the syngeneic TS/A mouse tumor model. ...Additional support to the broad functional immunomodulation of neoplastic cells by DNA hypomethylating agents derives from the immunohistochemical finding that the expression of MHC class I molecules was up-regulated in 5-AZA-CdR-treated tumors.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S; anti-mouse MHC Class I (H-2Db) 28-14-8S mAb

A potential role for shed soluble major histocompatibility class I molecules as modulators of neurite outgrowth.
Washburn, L. R., et al. PLoS One. 2011 Mar 31;6(3):e18439. doi: 10.1371/journal.pone.0018439. PMID: 21483793
Classical major histocompatability complex class I (MHCI) Ia molecules play a central role in immune surveillance. ...The MHCI complex is tripartite, consisting of a heavy chain (≈44 kDa), β2 microglobulin (β2M) light chain (≈12 kDa) and a short polypeptide of 8–10 amino acids from a cytosolic antigen that is bound to a groove in the heavy chain. ...MHCI on the cell surface is screened by CD8− T cells using T cell receptors that were generated by gene rearrangement to identify cells expressing foreign antigens. ...MHCI-deficient mice have an exuberance of retinal projections in their thalamus and enhanced long term potentiation, indicating that MHCI participates in activity-dependent synaptic elimination. ...We have been interested in classical MHCI's effects on wildtype neurons. We observed that picomolar levels of recombinant soluble MHCI monomers could inhibit neurite outgrowth from embryonic mouse retina explants in culture.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S in animal model; anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in animal model

Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.
Li, X.-L., et al. PLoS One. 2009 Jul 24;4(7):e6385. doi: 10.1371/journal.pone.0006385. PMID: 19629186
However, tumors deficient in major histocompatibility complex class I (MHC-I) antigen presentation often evade immune-mediated destruction. ...TAP is composed of TAP1 and TAP2 subunits whose function is to transport cytosolic-generated peptides into the lumen of the endoplasmic reticulum (ER) for MHC-I binding, followed by transport of MHC-I/peptide complexes to the cell surface. ...The CMT.64 cells are defective in both TAP1 and TAP2 at transcriptional and translational levels and express low levels of MHC-I molecules. ...Thus, TAP-independent epitopes which are expressed on CMT.64 cells may not be presented on the DC's surface for T-cell priming, because these epitopes similar to the peptides presented on TAP-deficient RMA-S cells [25] generally display low ability for MHC-I binding, and therefore cannot compete with TAP-dependent epitopes for MHC-I binding and DC's surface expression. ...Surface MHC-I and B7.1 expression was detected by a FACScan analyzer (Becton Dickinson, Mountain View, CA) using direct and indirect immunofluorescence.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S in cancer research; anti-mouse MHC Class I (H-2Db) 28-14-8S antibody in vivo

Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape.
Hengel, H., et al. J Virol. 1994 Jan;68(1):289-97. doi: 10.1128/JVI.68.1.289-297.1994. PMID: 8254740
Major histocompatibility complex (MHC) class I moleculesbind peptides derived from endogenously synthesized proteinsand present them at the cell surface to CD8+ T lymphocytes. ...After trypsiniza-tion, washing, and counting of cells, peptides were extractedwith trifluoroacetic acid from whole cell lysates (-4 x 107cells) and separated first by size on a Sephadex G-25 columnand subsequently on a reverse-phase high-pressure liquidchromatography (HPLC) column. ...The restoration of antigen presentation therefore comprisestwo events. ...The following mono-clonal antibodies (MAbs) were used: 28-14-8S (anti-Ld03)(ATCC HB 27), 64-3-7 (anti-Ldox2, selective for Ldalt) (24),30-5-7 (anti-Ldox2, selective for ,B2m-associated Ld) (24), 34-5-8S (anti-Dc') (ATCC HB 102), GK1.5 (anti-CD4) (ATCCTIB 207), YTS-169.4 (anti-CD8) (6), YTS-191.1 (anti-CD4+)(6), R4-6A2 (anti-murine IFN-y) (ATCC HB 170), AN-18(anti-murine IFN-y) (32); and Vlq (anti-murine tumor necro-sis factor) (12). Anti-MCMV serum was collected from latentlyinfected BALB/c mice. ...Inbrief, quantitative precipitations were performed sequentiallywith ascitic fluids of the MAb 64-3-7, followed by 28-14-8S and34-5-8S.
Tags: anti-mouse MHC Class I (H-2Db) 28-14-8S antibody of low endotoxin; anti-mouse MHC Class I (H-2Db) antibody 28-14-8S

For more references about Anti-mouse MHC Class I (H-2Db) Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following recombinant MHC/HLA monoclonal antibodies:
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2) Monoclonal Antibodies (Clone M1/42.3.9.8.HLK)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Db) Monoclonal Antibodies (Clone 28-14-8S)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kb) Monoclonal Antibodies (Clone Y-3)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kb) Monoclonal Antibodies (Clone AF6-88.5.3)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kd, H-2Dd) Monoclonal Antibodies (Clone 34-1-2S)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kd) Monoclonal Antibodies (Clone SF1-1.1.10)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kk, H-2Dk) Monoclonal Antibodies (Clone 15-3-1S)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kk, H-2Dk) Monoclonal Antibodies (Clone 16-1-2N)
In Vivo Grade Recombinant Anti-mouse MHC Class I (H-2Kk) Monoclonal Antibodies (Clone AF3-12.1.3)
In Vivo Grade Recombinant Anti-mouse MHC Class II (I-A) Monoclonal Antibodies (Clone Y-3P)
In Vivo Grade Recombinant Anti-mouse MHC Class II (I-A/I-E) Monoclonal Antibodies (Clone M5/114.15.2)
In Vivo Grade Recombinant Anti-mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As, I-Ag7) Monoclonal Antibodies (Clone 10-3.6.2)
In Vivo Grade Recombinant Anti-mouse MHC Class II (I-Ek/RT1-D) Monoclonal Antibodies (Clone 14-4-4S)
In Vivo Grade Recombinant Anti-mouse MHC Class II (Beta chain) Monoclonal Antibodies (Clone KL277)
In Vivo Grade Recombinant Anti-human HLA-ABC Monoclonal Antibodies (Clone W6/32)
In Vivo Grade Recombinant Anti-human HLA-DR Monoclonal Antibodies (Clone L243)
In Vivo Grade Recombinant Anti-human HLA-DR/DP/DQ Monoclonal Antibodies (Clone F3.3)
In Vivo Grade Recombinant Anti-human HLA Class I Heavy Chain Monoclonal Antibodies (Clone HC10)
In Vivo Grade Recombinant Anti-human HLA class II DR/DQ Monoclonal Antibodies (Clone 9.3F10)
In Vivo Grade Recombinant Anti-human MHC Class II HLA-DP/DQ/DR Monoclonal Antibodies (Clone IVA12)
Recombinant Anti-human HLA-ABC Monoclonal Antibodies (Clone W6/32) for flow cytometry
Recombinant Anti-human HLA-DR Monoclonal Antibodies (Clone L243) for flow cytometry
Recombinant Anti-human HLA-DR/DP/DQ Monoclonal Antibodies (Clone F3.3) for flow cytometry
Recombinant Anti-human HLA Class I Heavy Chain Monoclonal Antibodies (Clone HC10) for flow cytometry
Recombinant Anti-human HLA class II DR/DQ Monoclonal Antibodies (Clone 9.3F10) for flow cytometry